We are excited to announce the publication of a new paper titled “Wellness in the Modulator Era: An Observational Study of the Impact of CFTR Modulator Therapy on the Well-being of People with Cystic Fibrosis” in the Journal of Cystic Fibrosis. This work includes contributions from our very own Aricca Van Citters and Joel King.
This study explores the impact of CFTR modulator therapies on the health-related quality of life (HRQoL) and well-being of people with cystic fibrosis (PwCF). Through a cross-sectional observational approach, the Wellness in the Modulator Era (Well-ME) survey gathered data from adult PwCF and caregivers of children with CF. Key findings include:
- People taking modulator therapy report improved physical and social well-being.
- People taking modulator therapy report an improved CF care experience.
- People with cystic fibrosis face challenges in mental and financial well-being.
- More support may be needed for those not using or ineligible for modulator therapy.
We invite you to read the full article here.